NIPC Law

Human Respiratory Syncytial Virus Author NIAID   Licence CC BY 2.0   Source    Wikimedia Commons   Jane Lambert Patents Court (Mr Justice Mellor)  Pfizer Ltd v GlaxoSmithKline Biologicals SA and another 2024] EWHC 2523 (Pat) (07 Oct 202 4) Pfizer Ltd v GlaxoSmithKline Biologicals SA and anothe r [2025] EWHC 52 (Pat) (16 Jan 2025) This was a claim by Pfizer Ltd. ("Pfizer")  for the revocation of  EP (UK) 3 109 258 ("258") and EP (UK) 2 222 710 ("710")  under s.72 (1) (a)  of the Patents Act 1977 on the grounds that the inventions for which those patents were granted were not patentable.  The patents were held by  GlaxoSmithKline Biologicals SA  and  ID Biomedical Corporation of Quebec  (collectively "GSK").   The reason for the litigation was that both Pfizer and GSK had developed vaccines for respiratory syncytial virus ("RSV")  that were about to receive marketing approval in the UK....

Office of the President of the University of California Author Coolcaesar   Licence CC BY-SA 4.0    Source Wikimedia Common s   Jane Lambert Court of Appeal (Lords Justices Arnold, Snowden and Zacaroli)  Accord Healthcare Ltd and others v Regents of the University of California and another [2025] EWCA Civ 936 (23 July 2025) This was an appeal by Accord Healthcare Limited and other generic pharmaceutical manufacturers against Mr Justice Mellor's dismissal of their claims for revocation of European Patent (UK) No. 1 893 196 (“the patent”) and SPC No. SPC/GB13/079 (“the SPC”)  on grounds of obviousness , implausibility and insufficiency in Accord Healthcare Ltd and others v Regents of the University of California and another [2024] EWHC 2524 (Pat) (8 Oct 2024). They appealed with the permission of Lord Justice Arnold.  His lordship heard the appeal with Lord Justice Snowden and Lord Justice Zacaroli on 2 July 2025.  The Lord Justices handed...

Omalizumab structure Authors  Manav Segal, Jeffrey R Stokes, Thomas B. Casale Licence CC BY 2,5 Source Wikimedia Commons Jane Lambert Patents Court (HH Judge Hacon)  Celltrion Inc v Genentech, Inc and another [2025] EWHC 174 (Pat) (30 Jan 2025)   This was an action by Celltrion Inc ("Celltrion") for the revocation of European patent (UK)  3 805 248 B1  for a "Process for concentration of antibodies and therapeutic products thereof" ("the patent") held by Genentech Inc ("Genentech") and Novartis AG ("Novartis") and a counterclaim by Genentech and Novartis against Celltrion and its UK subsidiary for infringement.  The action and counterclaim were tried by His Honour Judge Hacon between 24 Oct 2024 and 1 Nov 2024.  The learned judge delivered judgment on 30 Jan 2025 (see  Celltrion Inc v Genentech, Inc and another  [2025] EWHC 174 (Pat) (30 Jan 2025)).  By para [193] of his judgment, he found that the patent was valid and infringed. Th...